OncLive Insights

This discussion focuses on the evolving role of first line maintenance therapy in extensive stage small cell lung cancer, with focused discussion of the phase 3 IMforte trial evaluating atezolizumab plus lurbinectedin. Faculty review efficacy data, safety considerations, patient selection, management of brain metastases, and case based decision making to contextualize how maintenance strategies are being integrated into contemporary practice.

This OncLive Insights program reviews the rapidly expanding role of antibody-drug conjugates (ADCs) across the breast cancer continuum and their growing impact on clinical decision-making. In early-stage HER2-positive disease, emerging data from DESTINY-Breast trials support the movement of trastuzumab deruxtecan into neoadjuvant and adjuvant settings for selected high-risk patients, while highlighting the need for careful toxicity monitoring. In metastatic HER2-positive disease, ADCs are moving into the first-line setting with evolving strategies for treatment duration and maintenance. For hormone receptor–positive HER2-low disease, ADCs have redefined classification and earlier treatment sequencing, with additional agents providing options after chemotherapy. In metastatic triple-negative breast cancer, multiple ADCs, either alone or combined with immunotherapy, are reshaping first-line care. Across subtypes, key challenges include optimal sequencing, cumulative toxicity management, and patient selection. Looking ahead, next-generation ADCs, biomarker-driven strategies, and treatment de-escalation approaches are expected to further personalize therapy and improve outcomes.

This program focuses on integrating emerging oral selective estrogen receptor degraders (SERDs) into the treatment of ER-positive, HER2-negative metastatic breast cancer. Drs. Jason Mouabbi and Aditya Bardia review current and investigational agents such as elacestrant, imlunestrant, camizestrant, giredestrant, and others, emphasizing differences in tolerability and side-effect profiles. Oral SERDs are generally better tolerated than traditional endocrine therapies, with side effects ranging from gastrointestinal discomfort to bradycardia and visual disturbances, highlighting the importance of aligning therapy choice with patient lifestyle and preferences. Combination strategies with targeted therapies, including CDK4/6 inhibitors and everolimus, show enhanced efficacy but require careful consideration of overlapping toxicities. Using a case-based approach, the program demonstrates practical decision-making, including sequencing, monitoring with scans, tumor markers, and plasma-based genotyping, and underscores the role of patient-centered care. The overarching takeaway is the critical importance of molecular testing to identify ESR1 and other actionable mutations, enabling personalized, effective, and safe therapy selection.

Experts review recent evidence shaping prostate cancer care, including emerging survival data, sion outcomes, and findings across biochemical recurrence and metastatic castration-sensitive prostate cancer.

Experts discuss practical management considerations, including patient selection for monotherapy, long term tolerability, fatigue management strategies, and the role of exercise in supporting patients on therapy.

Experts explore how alterations within the PI3K/AKT/PTEN pathway influence treatment decisions in HR+/HER2-negative advanced breast cancer, and we will take a focused look at strategies for managing key adverse events associated with therapies targeting this pathway, including diarrhea, hyperglycemia, and rash.

Experts integrate perspectives from medical oncology, pharmacy, and advanced practice nursing to review practical approaches to patient education, monitoring, and supportive care, along with considerations that support treatment adherence and improve patient experience.

Breast cancer experts discuss how long-term data from the monarchE and NATALEE trials inform patient selection, drug choice, and real-world use of adjuvant CDK4/6 inhibitors in high-risk HR-positive, HER2-negative early breast cancer.

Experts examine the evolving role of TROP2 in non–small cell lung cancer, highlighting the limitations of conventional IHC and the potential of quantitative continuous scoring (QCS) and normalized membrane ratio (NMR) as more reliable, predictive biomarkers for TROP2-directed antibody–drug conjugates.

This OncLive Insights program features Drs. Sandip Patel and Jonathan Riess in an in-depth discussion on current and emerging strategies for managing HER2-mutated non-small cell lung cancer (NSCLC). The experts review the evolving diagnostic landscape, emphasizing the importance of comprehensive molecular testing, both tissue and plasma, to identify HER2 mutations and HER2 IHC 3+ overexpression. They examine the clinical integration of targeted therapies including trastuzumab deruxtecan (T-DXd), zongertinib, and the recently reported sevabertinib, highlighting their efficacy, safety profiles, and roles across lines of therapy. Key challenges are addressed, such as CNS metastases, sequencing uncertainty, toxicity monitoring, and the need for resistance-based treatment strategies. The discussion concludes with a forward-looking perspective on next-generation HER2 inhibitors, ADC development, CNS-penetrant agents, and opportunities to advance care through clinical trials and real-world evidence.

This OncLive Insights program features Dr Hatim Husain and Dr Surbhi Singhal discussing how genomic testing guides modern lung cancer care from diagnosis through treatment selection and monitoring. The panel reviews the roles of tissue biopsy, liquid biopsy, and next generation sequencing, highlighting how timing, test choice, and test limitations affect clinical decisions. Using real world examples, they show how molecular profiling, ctDNA, and emerging biomarkers help personalize therapy, track resistance, and improve patient outcomes, while also addressing cost, access, and future directions in precision oncology.

In this OncLive® PV Insights program, expert faculty discuss recent advances in the management of polycythemia vera, with a focus on expanding the definition of disease control beyond hematologic parameters. The conversation highlights evolving perspectives on symptom burden, thrombotic risk, iron regulation, and emerging therapies, including insights from recent clinical trials. Faculty also explored how clinicians can integrate patient experience, functional outcomes, and molecular insights into real world treatment decisions to improve long term patient outcomes in PV.

In this video series, we’ll discuss complex patient case scenarios in HER2-positive metastatic breast cancer, exploring current standards of care, emerging clinical data, and evolving therapeutic strategies. Our goal is to provide practical, evidence-based insights to help clinicians navigate treatment sequencing, manage toxicities, and apply the latest research, such as findings from DESTINY-Breast09 and upcoming SABCS patient-reported outcomes, to optimize outcomes for patients with HER2+ disease.

Editorial note: This program was recorded prior to the FDA approval of fam-trastuzumab deruxtecan-nxki in combination with pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast cancer. Discussion reflects the clinical data, regulatory status, and treatment considerations available at the time of filming.

For additional context on the recent FDA approval, view our related OncLive editorial coverage:

FDA Approves T-DXd Plus Pertuzumab for HER2+ Breast Cancer | OncLive

In this OncLive® Insights program, Paul Richardson, MD, is joined by Hans Lee, MD, to examine the evolving role of BCMA-directed bispecific antibodies in the treatment of relapsed or refractory multiple myeloma. The discussion focuses on patients who are triple-class exposed or refractory and face limited options with conventional therapies. Drs Richardson and Lee review the biologic rationale for targeting BCMA, compare available therapeutic platforms including CAR T-cell therapy, antibody-drug conjugates, and bispecific antibodies, and explore how these approaches are being sequenced in real-world practice. The experts highlight linvoseltamab, including key design elements and outcomes from the LINKER-MM1 trial, safety considerations such as cytokine release syndrome and infection risk, and practical aspects of step-up dosing and treatment de-escalation. The conversation also highlights challenges and opportunities in community oncology settings, offering practical insights into integrating BCMA-directed bispecifics into everyday clinical care.

Panelists discuss how earlier recognition, targeted testing, guideline-informed screening, and coordinated oncology–neurology care can improve diagnosis and management of CA-LEMS, particularly when linked to small cell lung cancer.

This discussion outlines a panel discussion on advances in advanced/recurrent endometrial cancer, emphasizing how long-term trial outcomes and real-world evidence are reshaping treatment selection, sequencing, toxicity management, and future priorities across molecular subgroups.

In this OncLive® Insights: My Treatment Approach program, Amitkumar Mehta, MD, and nurse practitioner Lucy Bailey discuss the rapidly evolving treatment landscape for relapsed/refractory follicular lymphoma. With the emergence of bispecific antibodies, CD19-directed therapies, and CAR T-cell therapy, clinicians now have an unprecedented range of options beyond traditional regimens such as rituximab + lenalidomide (R²) or bendamustine-based chemoimmunotherapy. The faculty review how to evaluate patients after relapse, balance efficacy with toxicity, and select optimal therapies based on disease biology, comorbidities, social factors, and practice setting. They highlight the importance of monitoring for transformation, the nuances of lenalidomide dosing, and the expanding role of community practices in administering novel agents. Through case-based discussions, they outline practical strategies to enhance safety, minimize hospitalization, and foster partnerships between academic centers and community clinicians. The program provides clear, actionable guidance for optimizing outcomes in patients with relapsed follicular lymphoma.

Experts discuss complex hypothetical patient case scenarios in non–small cell lung cancer (NSCLC), highlighting current screening and testing methodologies, diagnostic challenges, and best practices in management.

• Discuss evolving treatment landscape of HER2-directed therapies in NSCLC
• Evaluate sequencing strategies for HER2-targeted ADCs and TKIs
• Interpret the role of HER2 mutation and overexpression testing in clinical practice

This series highlights an international exchange between a US oncologist and a German oncologist on screening and testing practices for non-small cell lung cancer (NSCLC). Experts discuss the current landscape of testing panels and share practical pearls on improving efficiencies in daily practice.

Panelists discuss how evolving molecular classification, improved detection methods, and emerging data from novel tyrosine kinase inhibitors like firmonertinib are transforming the treatment of non–small cell lung cancer (NSCLC) with EGFR PACC mutations. They highlight a future where advanced sequencing and innovative therapeutic strategies will enable more precise, effective, and durable management of this complex molecular subset.

Panelists discuss the role of biomarker testing, when it should be performed, and how comprehensive profiling can shape individualized care. Panelists discuss the evolving treatment landscape for FGFR2b-positive gastric cancer, highlighting key ongoing and late-phase trials as well as future approvals on the horizon. Panelists discuss how biomarker-driven decision-making guides therapy selection, considering how molecular findings, clinical characteristics, and emerging data influence both first-line and subsequent treatment strategies.

Panelists discuss evolving first- and second-line treatment strategies for extensive-stage small cell lung cancer, emphasizing evidence-based integration of immunotherapy, personalized maintenance approaches, toxicity management, and the promise of emerging targeted and immune-based therapies to improve survival and quality of life.

Panelists discuss the rapidly evolving frontline management of advanced renal cell carcinoma, highlighting progress in combination immunotherapy, precision-based treatment, toxicity management, and the promise of emerging therapies that are reshaping the standard of care.

Panelists discuss how innovative treatment strategies, including immune-based and cell-directed therapies, are transforming care for patients with relapsed or refractory follicular and marginal zone lymphomas by improving long-term outcomes, enhancing safety, and prioritizing patient-centered approaches that balance efficacy, quality of life, and access to advanced, personalized treatment options.

Panelists discuss how patients with unresectable hepatocellular carcinoma present with dual challenges of managing both the cancer and underlying cirrhotic liver disease, emphasizing the complexity of applying clinical trial data from patients with Child-Pugh A status to the more heterogeneous Child-Pugh B population commonly seen in practice.

Panelists discuss how intravenous administration of immune checkpoint inhibitors creates operational challenges, including infusion chair bottlenecks, complex scheduling, venous access difficulties, and time burdens for patients, while subcutaneous formulations offer potential solutions through simplified delivery, reduced infusion center strain, and improved patient convenience.

Panelists discuss how recent FDA-approved therapies for chronic graft-vs-host disease (GVHD; ibrutinib, ruxolitinib, belumosudil, and axatilimab) have transformed treatment approaches by enabling earlier intervention after steroid failure, targeting distinct immunological pathways, and improving patient outcomes through personalized treatment sequencing based on organ involvement, toxicity profiles, and practical considerations like oral vs intravenous administration.

Panelists discuss how CAR T-cell therapy has evolved from a highly toxic inpatient treatment to a safer, increasingly accessible therapy that can often be administered on an outpatient basis, with improved patient outcomes when referred early in the treatment journey and enhanced collaboration between academic centers and community oncologists for optimal patient care.